Aurobindo Pharma is aiming to complete its Rs 2,000 crore Penicillin G (Pen G) plant in Andhra Pradesh by March 2024 even as the trial or the pilot batches will take place starting October next year onwards. Out of Rs 2000 crore, the drug maker has already spent around Rs 500 crore and Rs 1,500 crore is going to be spent in the coming year.
The production capacity of the plant will be around 15,000 tonnes annually. The plant been approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
